Literature DB >> 33389528

Programmed cell death 1 (PDCD1) gene haplotypes and susceptibility of patients to basal cell carcinoma.

Farshid Fathi1, Batool Zamani2, Ahmad Piroozmand2,3, Samaneh Mozafarpoor4, Effat Seyedhashemi5, Reza ArefNezhad6, Hossein Motedayyen7.   

Abstract

Programmed death-1 (PD-1), as an immunoinhibitory receptor encoded by programmed cell death-1 (PDCD1) gene, has a pivotal role in tolerance to self-antigens. Mutations of PDCD1 may participate in susceptibility to basal cell carcinoma (BCC) as the most common of skin cancer. We studied the impacts of two single nucleotide polymorphisms (SNPs) within PDCD1 and their haplotypes in BCC susceptibility in an Iranian population. The blood samples were collected from 210 BCC and 220 healthy individuals. After the extraction of genomic DNA, the genotypes and alleles of PD1.1 G/A (rs36084323) and PD1.6 G/A (rs10204525) SNPs were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Four haplotypes were estimated by these SNPs. Our data revealed that genotype and allele frequencies of PD1.1 and PD1.6 polymorphisms in BCC patients were similar to those in healthy individuals. The results of estimated haplotypes for PDCD1 indicated that GG and AA haplotypes of PDCD1 had protective effects on BCC susceptibility (OR = 0.7, 95% CI = 0.51-0.96, p = 0.03 and OR = 0.57, 95% CI = 0.35-0.91, p = 0.02, respectively), while GA and AG haplotypes served as the risk factors for developing BCC (OR = 1.76, 95% CI = 1.09-2.84, p = 0.02 and OR = 3.87, 95% CI = 1.95-7.69, p = <0.001, respectively). Based on these findings, frequency distributions of PDCD1 haplotypes have important roles in the determination of BCC development in the Iranian population. However, larger multicenter studies are required to confirm this conclusion.

Entities:  

Keywords:  Basal cell carcinoma; Haplotype; Polymorphism; Programmed cell death-1

Mesh:

Substances:

Year:  2021        PMID: 33389528     DOI: 10.1007/s11033-020-06115-w

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  38 in total

Review 1.  Molecular aetiology and pathogenesis of basal cell carcinoma.

Authors:  C M L J Tilli; M A M Van Steensel; G A M Krekels; H A M Neumann; F C S Ramaekers
Journal:  Br J Dermatol       Date:  2005-06       Impact factor: 9.302

Review 2.  Dermoscopy of basal cell carcinoma.

Authors:  A Wozniak-Rito; I Zalaudek; L Rudnicka
Journal:  Clin Exp Dermatol       Date:  2018-01-17       Impact factor: 3.470

Review 3.  Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.

Authors:  Ketty Peris; Maria Concetta Fargnoli; Claus Garbe; Roland Kaufmann; Lars Bastholt; Nicole Basset Seguin; Veronique Bataille; Veronique Del Marmol; Reinhard Dummer; Catherine A Harwood; Axel Hauschild; Christoph Höller; Merete Haedersdal; Josep Malvehy; Mark R Middleton; Colin A Morton; Eduardo Nagore; Alexander J Stratigos; Rolf-Markus Szeimies; Luca Tagliaferri; Myrto Trakatelli; Iris Zalaudek; Alexander Eggermont; Jean Jacques Grob
Journal:  Eur J Cancer       Date:  2019-07-06       Impact factor: 9.162

4.  Aging and the treatment of basal cell carcinoma.

Authors:  Shreya Sreekantaswamy; Justin Endo; Amy Chen; Daniel Butler; Lily Morrison; Eleni Linos
Journal:  Clin Dermatol       Date:  2019-06-16       Impact factor: 3.541

Review 5.  Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action.

Authors:  Ni Zhang; Jingyao Tu; Xue Wang; Qian Chu
Journal:  Immunotherapy       Date:  2019-01-30       Impact factor: 4.196

Review 6.  Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations.

Authors:  Michael C Cameron; Erica Lee; Brian P Hibler; Christopher A Barker; Shoko Mori; Miguel Cordova; Kishwer S Nehal; Anthony M Rossi
Journal:  J Am Acad Dermatol       Date:  2018-05-18       Impact factor: 11.527

7.  Environmental risk factors predisposing to the development of basal cell carcinoma.

Authors:  Malgorzata Zak-Prelich; Joanna Narbutt; Anna Sysa-Jedrzejowska
Journal:  Dermatol Surg       Date:  2004-02       Impact factor: 3.398

8.  TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation.

Authors:  Helena Pópulo; Paula Boaventura; João Vinagre; Rui Batista; Adélia Mendes; Regina Caldas; Joana Pardal; Filomena Azevedo; Mrinalini Honavar; Isabel Guimarães; José Manuel Lopes; Manuel Sobrinho-Simões; Paula Soares
Journal:  J Invest Dermatol       Date:  2014-04-01       Impact factor: 8.551

Review 9.  Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management.

Authors:  Alexander G Marzuka; Samuel E Book
Journal:  Yale J Biol Med       Date:  2015-06-01

10.  Hepatic expression of programmed death-1 (PD-1) and its ligand, PD-L1, in children with autoimmune hepatitis: relation to treatment response.

Authors:  Hala A Agina; Nermine A Ehsan; Taghreed A Abd-Elaziz; Ghada A Abd-Elfatah; Eman M Said; Mostafa M Sira
Journal:  Clin Exp Hepatol       Date:  2019-09-05
View more
  2 in total

1.  The Immunogenetics of Non-melanoma Skin Cancer.

Authors:  Sabha Mushtaq
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  High Expression of CSF-1R Predicts Poor Prognosis and CSF-1Rhigh Tumor-Associated Macrophages Inhibit Anti-Tumor Immunity in Colon Adenocarcinoma.

Authors:  Xingchao Wang; Jianfeng Zhang; Baoying Hu; Fei Qian
Journal:  Front Oncol       Date:  2022-04-04       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.